That included Sanofi and Regeneron’s rival PCSK9 inhibitor Praluent (alirocumab ... spot of PCSK9 and blocks PCSK9 from binding to LDL receptors,” concluded the justices.

PCSK9, which mediates post-translational destruction of LDL receptors, is raised in HoFH and is further raised by statins. LDL-C, following apheresis, quickly rebounds due to increased synthesis ...

The study also sheds light on how the PCSK9 variant drives metastasis. By degrading the LRP1 receptor on cancer cells, the variant appears to unleash a cascade of gene activation ideal for ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...

Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. Get Matt Maley’s top trade setups for a tariff-driven market, live this Wednesday at 6 PM ET. Reserve ...

HDL is reduced. PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial ...

This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen’s size and unrelated product portfolio, their ...